About US
Contact us
-
Attend the FierceBiotech Executive Breakfast at JP MorganShares of Eli Lilly were up nearly 3% in premarket trading on Wednesday after the company provided a revenue and profit forecast for next year that beat analysts’ expectations. Thenews, which was rele2018/12/20
-
GSK, Pfizer go for radical makeovers with giant consumer combo destined for spinoffTurns out, after GlaxoSmithKline walked away from a chance to scoop up Pfizer’s consumer health business in March, it got another opportunity to team up on a deal. The two Big Pharma companies have de2018/12/20
-
Lilly's Taltz beats out AbbVie's megadrug Humira in psoriatic arthritis showdownWhat’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis (PsA). Monday, the Indianapolis drugmaker said its anti-2018/12/19
-
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and JapanWith its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities2018/12/19
-
Astellas buys Potenza Therapeutics for up to $405mJapanese pharmaceutical company Astellas Pharma has acquired US-based Potenza Therapeutics for a total consideration of up to $405m. The deal is made possible as Astellas exercised its option to buy2018/12/18
-
AbbVie licences BioArctic’s Parkinson’s disease portfolioSwedish biopharma company BioArctic has secured clearance from US Federal Trade Commission (FTC) to out-licence its alpha-synuclein antibody portfolio to AbbVie. The portfolio is intended for the tre2018/12/18
-
Merck looks past Sanofi's dengue woes in development deal with Brazilian vaccine instituteEven after Sanofi suffered a costly dengue vaccine controversy last year, fellow pharma giant Merck & Co. isn’t backing away from the field. Instead, it hasstrucka new partnership with Brazil’s Bu2018/12/17
-
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trialAstraZeneca felt the blow last month whenMystic, a key trial examining its immuno-oncology drug Imfinzi in previously untreated lung cancer, failed. But now that the dust has settled, the company is l2018/12/17
-
Lilly teams up with AC Immune for Alzheimer’s drugEli Lilly has signed a licence and collaboration agreement with Swiss biotech AC Immune for the research and development of tau aggregation inhibitor small molecules to treat neurodegenerative disorde2018/12/14
-
NIH to support HIV care and prevention research in the USThe National Institute of Allergy and Infectious Diseases (NIAID), a National Institutes of Health (NIH) division, has announced plans to fund human immunodeficiency virus (HIV) care and prevention re2018/12/14